(Q43292657)

English

Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.

scientific article published in November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

Sébastien Dharancy

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Alexandre Louvet

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Philippe Mathurin

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Sylvie Deuffic-Burban

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Gérard Babany

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Isabelle Lonjon-Domanec

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Pierre Deltenre

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Valérie Canva-Delcambre

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Françoise Roudot-Thoraval

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

0 references

publication date

1 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

50

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1351-1359

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19676130%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Treatment of patients with chronic hepatitis C and normal ALT levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Natural history of initially mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

[Treatment of hepatitic C virus infection after the French 2002 Consensus Conference].

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Projecting future complications of chronic hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Market uptake of new antiviral drugs for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23159

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43292657&oldid=1607657118"